Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?

Acta Oncologica

Volumn 48, Issue 6, 2009, Pages 882-889

  Morgan, Claire ^a   Wagstaff, John ^a,b  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b SINGLETON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ARTHRALGIA; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HUMAN; IN VITRO STUDY; INJECTION SITE REACTION; JAW OSTEONECROSIS; KIDNEY DISEASE; KIDNEY INJURY; LOADING DRUG DOSE; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; REFLUX ESOPHAGITIS; VOMITING;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 70350696184     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860902874748     Document Type: Article

References (56)

1. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004;/11:/207-24.
2. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;/27:/165-76.
3. Clezardin P. Anti-tumour activity of zoledronic acid. Cancer Treat Rev 2005;/31(Suppl 3):/1-8.
4. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and - independent effects. Br J Cancer 2003;/88:/1631-40.
5. Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye JC, et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 2006;/6:/60.
6. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(12 Suppl): 2961-78.
7. Walker K, Olson MF. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev 2005;/15:/62-8.
8. Cameron D, Fallon M, Diel I. Ibandronate: Its role in metastatic breast cancer. Oncologist 2006;/11(Suppl 1):/ 27-33.
9. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 2008;/19:/420-32.
10. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;/96:/879-82. (Pubitemid 38807610)
11. Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 2005;/31(Suppl 3):/19-25.
12. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;/94:/ 1458-68.
13. Saad F, Chen YM, Gleason DM, Chin J. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007;/5:/390-6.
14. Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007;/5:/271-7.
15. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;/169:/2008-12.
16. Johnson K, Gable P, Kaime E, Luiken G, Castillos T, Hu J. Significant deterioration in renal function with the new bisphosphonate, zoledronic acid. Proc Am Soc Clin Oncol 2003;22 Abstract 2968.
17. McDermott RS, Kloth DD,Wang H, Hudes GR, Langer CJ. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model. J Support Oncol 2006;/4:/524-9.
18. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;/64:/ 281-9.
19. Balla J. The issue of renal safety of zoledronic acid from a nephrologist's point of view. Oncologist 2005;10:306-8 Author reply 11-2.
20. Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphosphonates: Current issues. J Support Oncol 2007;/5:/475-82.
21. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-9 Discussion -9.
22. Mazj S, Litchtman S. Renal dysfunction associated with bisphosphonate use: Retrospective analysis of 293 patients with respect to age and other clinical characteristics. J Clin Oncol 2004;22(22 Suppl 735) Abstract 8039.
23. Barot K, Wu S, Zhu X. Risk of renal dysfunction with zoledronic acid in patients with metastatic solid tumours. J Clin Oncol 2008;26(15 Suppl) Abstract 20530.
24. Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol 2007;/14:/1071-5.
25. Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001;/61:/4418-24.
26. Verdijk R, Franke HR, Wolbers F, Vermes I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 2007;/246:/308-12.
27. Journe F, Chaboteaux C, Magne N, Duvillier H, Laurent G, Body JJ. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res 2006;/8:/R2.
28. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;/15:/ 2211-21.
29. Journe F, Magne N, Chaboteaux C, Kinnaert E, Bauss F, Body JJ. Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines. Clin Exp Metastasis 2006;/23:/135-47.
30. Neudert M, Fischer C, Krempien B, Bauss F, Seibel MJ. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: Model characterisation and in vivo effects of ibandronate on tumour growth. Int J Cancer 2003;/107:/ 468-77.
31. Neudert M, Fischer C, Krempien B, Seibel MJ, Bauss F. A rapid histological score for the semiquantitative assessment of bone metastases in experimental models of breast cancer. Onkologie 2008;/31:/521-7.
32. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;/14:/1399-405.
33. Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;/90:/1133-7.
34. Dumon JC, Journe F, Kheddoumi N, Lagneaux L, Body JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004;45:521-8 Discussion 8-9.
35. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997;/57:/ 3890-4.
36. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;/62:/ 6538-44.
37. Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002;/5:/231-5.
38. Heidenreich A, Ohlmann C, Olbert P, Hegele A. High dose ibandronate is effective and well tolerated in the treatment of pain and hypercalacaemia due to metastatic urological cancer. Eur J Cancer 2003;/1(Suppl 5):/S270.
39. Coleman RE, Purohit OP, Black C, Vinholes JJ, Schlosser K, Huss H, et al. Double-blind, randomised, placebocontrolled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999;/10:/311-6.
40. Martin T, Grill V. Bisphosphonates - mechanisms of action. Aust Prescrib 2000;/23:/130-2.
41. Leyland-Jones B. Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease. Eur J Cancer Suppl 2004;/2:/9-12.
42. Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: A clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;/44:/951-65.
43. Cameron D. Patient management issues in metastatic bone disease. Semin Oncol 2004;31(5 Suppl 10):79-82.
44. Body JJ. Bisphosphonates for malignancy-related bone disease: Current status, future developments. Support Care Cancer 2006;/14:/408-18.
45. Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 2003;/191:/159-67.
46. Cal JC, Daley-Yates PT. Disposition and nephrotoxicity of 3- amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice. Toxicology 1990;/65:/179-97.
47. CEDR New and Generic Drug Approval Zometa (zoledronic acid) injection, Part 2, NDA 21-223, Pharmacol Rev, Pharmacokinet. Summary (http://www.fda.gov/ cder/foi/nda/ 2001/21-223-Zormeta-pharmr-P2.pdf). 1998.
48. Pfister T, Atzpodien E, Bauss F. Preclinical renal safety profile of ibandronate. Bone 2008;/42(Suppl 1):/S105-6.
49. Polascik TJ, Given RW, Metzger C, Julian SR, Vestal JC, Karlin GS, et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 2005;/66:/1054-9.
50. Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, et al. The risk of renal impairment in hormonerefractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007;/109:/1090-6. (Pubitemid 46435387)
51. Lameire NH, Flombaum CD, Moreau D, Ronco C. Acute renal failure in cancer patients. Ann Med 2005;/37:/13-25.
52. Polascik TJ, Mouraviev V. Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag 2008;/4:/261-8.
53. Carey JJ, Palomo L. Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk? Cleve Clin J Med 2008;/75:/871-9.
54. Reid IR. Osteonecrosis of the jaw: Who gets it, and why? Bone 2009;/44:/4-10.
55. Wardley A, Body JJ, Neary MP. A time-in-motion study of oral ibandronate versus iv zoledronic acid for treatment of metastatic bone disease in breast cancer patients. J Clin Oncol 2005;/23:/16s.
56. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004;/9(Suppl 4):/28-37.